Circulation · 2008 · 69 citations · 27 references
MedicineCardiologyInternal MedicineClinical CardiologyDiabetologyInterventional CardiologyCardiovascular DiseaseCoronary AngioplastyCoronary Artery DiseaseIschemic Heart DiseasePercutaneous Coronary InterventionClinical Outcomes After Percutaneous Coronary InterventionCoronary StentingDiabetes-associated Cardiac RiskPercutaneous Coronary Intervention CareTarget Lesion Revascularization
BACKGROUND: The long-term effectiveness of drug-eluting stents (DES) in unselected diabetics in routine practice is currently unclear. METHODS AND RESULTS: To evaluate the long-term effectiveness of bare metal stents and DES in a real-world setting of diabetic patients, we analyzed 2-year follow-up data from all diabetic patients with de novo lesions enrolled in a prospective Web-based multicenter registry (Registro Regionale Angioplastiche dell'Emilia-Romagna; study period, 2002 to 2004) comprising all 13 hospitals performing percutaneous coronary interventions in the Emilia-Romagna region of Italy. Among the 1648 eligible patients treated with either bare metal stents alone (n=1089) or DES alone (n=559), 27% were insulin dependent and 83% had multivessel coronary disease. At 2 years, use of DES was associated with lower crude incidence of major adverse cardiac advents (all-cause mortality, nonfatal myocardial infarction, and target vessel revascularization) compared with bare metal stents (22.5% versus 28.1%; P=0.01). After propensity score adjustment, only target vessel revascularization appeared significantly lower in the DES group (11.6% versus 15.0%; hazard ratio, 0.66; 95% confidence interval, 0.46 to 0.96; P=0.041). Two-year angiographic stent thrombosis occurred in 1.5% DES patients and 0.7% of the bare-metal-stents patients (P=0.18). At Cox regression analysis, predictors of 2-year major adverse cardiac advents were left ventricular ejection fraction <35%, Charlson comorbidity index, insulin-dependent diabetes, and total lesion length. CONCLUSIONS: In this large, real-world, diabetic population, the use of DES was associated with a moderate reduction in the 2-year risk of target vessel revascularization, a benefit that was limited to non-insulin-dependent diabetic patients. Larger long-term studies are needed to clarify the long-term effectiveness and safety of such devices in diabetic patients.
27
Pathology of Drug-Eluting Stents in Humans
Michael Joner, Aloke V. Finn, Andrew Farb et al. · Journal of the American College of Cardiology · 2006 · 2.7K citations
Medicine, Cardiology, Pathology +11
Joost Daemen, Peter Wenaweser, Keiichi Tsuchida et al. · The Lancet · 2007 · 1.8K citations
Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
Gregg W. Stone, Jeffrey W. Moses, Stephen G. Ellis et al. · New England Journal of Medicine · 2007 · 1.6K citations · Full text